Plate Nº 33 · recorded October 10, 2026
Health & Medicine ResearchReported finding
Tirzepatide Activates Calorie-Burning Brown Fat in Obese Mice
University of Barcelona researchers report that tirzepatide, sold as Mounjaro and Zepbound, activated brown fat in obese mice — a finding that could explain benefits beyond appetite suppression, pending human confirmation.
By Marcus Bennett3 min read598 words
In brief
- Study published September 26, 2026 in the journal Biomedicine (DOI: 10.1016/j.biopha.2026.119057).
- Tirzepatide activated brown adipose tissue in obese mice fed a high-fat diet, compared with food-matched controls.
- The drug simultaneously targets the GIP and GLP-1 hormone receptors.
- Lead researcher Marion Peyrou is based at the University of Barcelona's Faculty of Biology, IRSJD, and CIBEROBN.
- Results are from mice only; human trials are required to confirm the brown-fat effect.
Tirzepatide, sold as Mounjaro and Zepbound, activated calorie-burning brown fat in obese mice in a study published September 26, 2026 in the journal Biomedicine. The University of Barcelona research suggests the popular obesity drug may boost metabolism in ways that have nothing to do with eating less.
What did the researchers find?
The team treated obese mice fed a high-fat diet with tirzepatide, then compared them with mice that received no drug but ate the same amount of food. That design let the scientists separate the drug's direct effects from those caused by reduced calorie intake.
Tirzepatide activated brown adipose tissue, the researchers report. Unlike white fat, which mostly stores energy, brown fat burns calories to generate heat.
"This activation is associated with an increased capacity to burn metabolic energy and with the production of batokines by brown adipose tissue, molecules that are beneficial for metabolism," said Marion Peyrou, a Ramón y Cajal researcher at UB's Faculty of Biology and the Institute of Biomedicine.
How does tirzepatide work?
Tirzepatide is approved in adults for weight management in obesity or overweight with comorbidities, and for poorly controlled type 2 diabetes. It works by targeting two hormone receptors at once: GIP and GLP-1.
That dual action drives substantial weight loss, mainly by cutting appetite. The new results hint at a second pathway.
"This drug not only reduces body weight, but also has beneficial effects on metabolism," Peyrou said. "Active brown adipose tissue 'burns' glucose and fat within the body, which would contribute to its positive effect not only in reducing body weight, but also in lowering blood glucose and fat levels, and improving metabolism."
Why does brown fat matter?
Scientists have long viewed brown fat activation as a promising route for treating obesity and related metabolic disease. Past drug attempts often flopped because of unwanted effects, especially on the heart.
Tirzepatide appears to dodge that problem.
"Tirzepatide, although it activates brown adipose tissue, does not have these negative effects; on the contrary, it shows cardiovascular benefits," Peyrou said.
She added: "If our findings are confirmed in humans, it would reinforce the importance of developing therapeutic strategies that not only reduce food intake but also increase energy expenditure and brown fat activation."
Could the finding apply to people?
The researchers stress that the data come from mice, not humans. Metabolism, fat distribution, and drug response can differ sharply between species.
"As this is a study conducted on mice, we must be cautious, as there may be significant differences between species in terms of metabolism regulation, adipose tissue distribution and response to drugs," Peyrou said. "Therefore, we need more clinical evidence on the action of these drugs on fat in humans."
The team also argues the work could shape prescribing. "Identifying which patient profiles could benefit most, for example those with more compromised energy expenditure, would open the door to more personalized medicine, based not only on appetite or weight control, but also on overall metabolic status," Peyrou said.
What are the limits of the study?
- Animal model only: obese mice on a high-fat diet, not human patients
- Tissue-level analysis impossible to perform in living humans
- No clinical trial data yet on brown-fat activation by tirzepatide in people
- Findings published in Biomedicine; DOI: 10.1016/j.biopha.2026.119057
The study was led by Peyrou alongside co-authors Alberto Mestres-Arenas, Tania Quesada-López, Albert Blasco-Roset, Marta Giralt, Francesc Villarroya, and Anna Planavila, based at UB, the Sant Joan de Déu Research Institute (IRSJD), and CIBER in Physiopathology of Obesity and Nutrition (CIBEROBN).
via dx.doi.org (Original)
More from Marcus Bennett
Nearby plates
- Phase 2 trial tests apitegromab to protect muscle during tirzepatide weight loss
- Semaglutide and Tirzepatide: Heart Outcomes Compared in Real-World Study
- Experimental Drug Combo Cuts Body Weight by Up to 23.3% in Diabetes Trial
- CBL-514 Injection Eliminates Fat Cells, Phase 2 Trial Shows
- Cleveland Clinic Examines What Happens After GLP-1 Discontinuation